Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years (IFM/DFCI2009)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Dana-Farber Cancer Institute
Celgene Corporation
Janssen-Cilag Ltd.
Information provided by (Responsible Party):
University Hospital, Toulouse
ClinicalTrials.gov Identifier:
NCT01191060
First received: April 16, 2010
Last updated: May 26, 2014
Last verified: May 2014

April 16, 2010
May 26, 2014
October 2010
September 2018   (final data collection date for primary outcome measure)
Progression Free Survival [ Time Frame: up to 4 years ] [ Designated as safety issue: Yes ]
To compare progression-free survival (PFS) between the Arm A and Arm B.up to 4 years or until progression
Progression Free Survival [ Time Frame: up to 4 years or until progression ] [ Designated as safety issue: Yes ]
To compare progression-free survival (PFS) between the Arm A and Arm B.
Complete list of historical versions of study NCT01191060 on ClinicalTrials.gov Archive Site
  • Response Rates [ Time Frame: up to 4 years ] [ Designated as safety issue: No ]
    -Response rates (RR) between the two arms up to 4 years or until progression
  • Time To Progression [ Time Frame: up to 4 years ] [ Designated as safety issue: No ]
    -Time to progression (TTP) between the two arms up to 4 years or until progression
  • Toxicity comparison [ Time Frame: up to 4 years ] [ Designated as safety issue: Yes ]
    -Toxicity comparison between the two arms randomization up to 4 years or until progression
  • Genetic prognostic groups definition [ Time Frame: up to 4 years ] [ Designated as safety issue: No ]
    -Genetic prognostic groups definition (evaluated by gene expression profiling-GEP) from randomization up to 4 years or until progression
  • Best treatment examination in each GEP-defined prognostic group. [ Time Frame: up to 4 years ] [ Designated as safety issue: No ]
    Best treatment examination in each GEP-defined prognostic group. from randomization up to 4 years or until progression
  • Response Rates [ Time Frame: up to 4 years or until progression ] [ Designated as safety issue: No ]
    -Response rates (RR) between the two arms
  • Time To Progression [ Time Frame: up to 4 years or until progression ] [ Designated as safety issue: No ]
    -Time to progression (TTP) between the two arms
  • Toxicity comparison [ Time Frame: from randomization up to 4 years or until progression ] [ Designated as safety issue: Yes ]
    -Toxicity comparison between the two arms
  • Genetic prognostic groups definition [ Time Frame: from randomization up to 4 years or until progression ] [ Designated as safety issue: No ]
    -Genetic prognostic groups definition (evaluated by gene expression profiling-GEP)
  • Best treatment examination in each GEP-defined prognostic group. [ Time Frame: from randomization up to 4 years or until progression ] [ Designated as safety issue: No ]
    Best treatment examination in each GEP-defined prognostic group.
Not Provided
Not Provided
 
Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years
Randomized Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib and Dexamethasone to High-Dose Treatment With ASCT in the Initial Management of Myeloma in Patients up to 65 Years of Age

Objective of this study is to determine if, in the era of novel drugs, high dose therapy (HDT) is still necessary in the initial management of multiple myeloma in younger patients. HDT as compared to conventional dose treatment would be considered superior if it significantly prolongs Progression-free survival (by at least 9 months).

Study design Phase III, multicenter, randomized, open-label study designed to evaluate the clinical benefit from the drug combination RVD without immediate high-dose therapy (HDT) followed by lenalidomide maintenance (Arm A) versus RVD plus HDT and PBSCT followed by lenalidomide maintenance (Arm B).

Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Multiple Myeloma
  • Progression Free Survival Prolongation
  • Disease Progression
  • Overall Survival
  • Drug: Lenalidomide, Bortézomib

    Lenalidomide/Bortézomib/Dexamethasone cycles:

    Number of cycles: 8 cycles for arm A

    Cycle length

    Dosage:

    • Lenalidomide: 25 mg/day on days 1-14 of each cycle
    • Bortézomib: 1.3 mg/m2 on days 1, 4, 8, and 11 for 1 cycle of each cycle

    Maintenance phase (12 months):

    Cycle length: 28 days Dosage: Lenalidomide: 10 mg/day continuously for 28 days during 3 months and if the participant tolerates 10 mg/day without complication, a dose increase to 15 mg/day will be allowed

    Other Names:
    • Lenalidomide (REVLIMID®)
    • Bortézomib (VELCADE®)
  • Drug: Lenalidomide, Bortézomib

    Lenalidomide/Bortézomib/Dexamethasone cycles:

    Number of cycles: 5 cycles for arm B

    Cycle length

    Dosage:

    • Lenalidomide: 25 mg/day on days 1-14 of each cycle
    • Bortézomib: 1.3 mg/m2 on days 1, 4, 8, and 11 for 1 cycle of each cycle

    Maintenance phase (12 months):

    Cycle length: 28 days Dosage: Lenalidomide: 10 mg/day continuously for 28 days during 3 months and if the participant tolerates 10 mg/day without complication, a dose increase to 15 mg/day will be allowed

    Other Names:
    • Lenalidomide (REVLIMID®)
    • Bortézomib (VELCADE®)
  • Experimental: B : RVD Treatment with ASCT

    RVD q 21 days (2 cycles) Collection of peripheral blood stem cells (PBSCs) using cyclophosphamide and GCSF (type Granocyte® or equivalent)

    Autologous stem cell transplant:

    Melphalan: infused over two days (day -2 and day -1) or as a single infusion (day-2) according to institutional practice Re-infusion of PBSCs RVD q 21 days (2 cycles) Maintenance Lenalidomide q28 days (12 months)

    Intervention: Drug: Lenalidomide, Bortézomib
  • Experimental: A : RVD treatment without ASCT
    RVD q 21 days (2 cycles) Collection of peripheral blood stem cells (PBSCs) using cyclophosphamide and GCSF (type Granocyte® or equivalent) RVD q 21 days (5 cycles) Maintenance Lenalidomide q28 days (12 months)
    Intervention: Drug: Lenalidomide, Bortézomib
Dunavin NC, Wei L, Elder P, Phillips GS, Benson DM Jr, Hofmeister CC, Penza S, Greenfield C, Rose KS, Rieser G, Merritt L, Ketcham J, Heerema N, Byrd JC, Devine SM, Efebera YA. Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myeloma. Leuk Lymphoma. 2013 Aug;54(8):1658-64. doi: 10.3109/10428194.2012.751528. Epub 2012 Dec 31.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
700
September 2020
September 2018   (final data collection date for primary outcome measure)

Inclusion Criteria for registration :

(with labs performed within 21 days of initiation of protocol therapy):

  • Patients diagnosed with multiple myeloma based on International Myeloma Foundation 2003 Diagnostic Criteria.
  • Patients must have symptomatic myeloma with myeloma-related organ damage.
  • Patients must have myeloma that is measurable by either serum or urine evaluation of the monoclonal component or by assay of serum free light chains.
  • Age between 18 and 65 years at the time of signing the informed consent document.
  • ECOG performance status <2 (Karnofsky ≥ 60%)
  • Negative HIV blood test

Exclusion Criteria for registration (section 4.2):

  • Participants must not have been treated with any prior systemic therapy for multiple myeloma. Treatment by localized radiotherapy is not an exclusion criterion if an interval of at least two weeks between the end of radiotherapy and initiation of protocol therapy entry in the study is observed. Similarly, the dose of corticosteroids received by the participant should not exceed the equivalent of 160 mg of dexamethasone over a two-week period before initiation of protocol therapy.
  • Primary amyloidosis (AL) or myeloma complicated by amylosis.
  • Participants may not be receiving any other study investigational agents.
  • Participants with known brain metastases
  • Poor tolerability or known allergy to any of the study drugs or compounds of similar chemical or biologic composition to study agents
  • Platelet count < 50,000/mm3 per µLwithin 21 days of initiation of protocol therapy. Transfusion within 7 days of screening is not allowed to meet platelet eligibility criteria.
  • ANC < 1,000 cells/mm3 within 21 days of initiation of protocol therapy. Growth factor within 7 days of screening is not allowed to meet ANC eligibility criteria.
  • Hemoglobin < 8.0 g/dL within 21 days of initiation of protocol therapy. Transfusion may be used to meet hemoglobin eligibility criteria.
  • Hepatic impairment, defined a bilirubin > 1.5 x institutional upper limit of normal (ULN) > 2 mg/dL (Patients with benign hyperbilirubinemia (e.g., Gilbert's syndrome) are eligible) and or AST (SGOT), or ALT (SGPT), or alkaline phosphatase > 2 x ULN
  • Renal insufficiency, defined as serum creatinine > 2.5 mg/dl and/or creatinine clearance < <40 60 ml/min (actual or calculated). The Cockgroft-Gault formula should be used for calculating creatinine clearance values, and may be located in Section 4.2
  • Respiratory compromise, defined as ventilation tests and with DLCO < 50%
  • Participant must not demonstrate with clinical signs of heart or coronary failure, or evidence of LVEF < 40%. Participant must not have with myocardial infarction within 6 months prior to enrollment or have New York Heart Association (NYHA Appendix VII) Class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any ECG abnormality at screening has to be documented by the investigator as not medically relevant.
  • Intercurrent illness including, but not limited to ongoing or active severe infection, known (active or not) infection with hepatitis B or C virus, poorly controlled diabetes, severe uncontrolled psychiatric disorder or psychiatric illness/social situations that would limit compliance with study requirements.
  • Participant with previous history of another malignant condition, except for basal cell carcinoma and stage I cervical cancer
  • Female participant who is pregnant or breast-feeding
  • Inability to comply with an anti-thrombotic treatment regimen
  • Peripheral neuropathy ≥ Grade 2 peripheral neuropathy on clinical examination within 21 days of initiation of protocol therapy
  • Mental illness likely to interfere with participation in the study and Adults under juridical protection
Both
18 Years to 65 Years
No
Contact information is only displayed when the study is recruiting subjects
France
 
NCT01191060
09 110 01
Yes
University Hospital, Toulouse
University Hospital, Toulouse
  • Dana-Farber Cancer Institute
  • Celgene Corporation
  • Janssen-Cilag Ltd.
Principal Investigator: MICHEL ATTAL, Pr University Hospital of Toulouse
University Hospital, Toulouse
May 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP